Biomerica, Inc. (NASDAQ:BMRA) Sees Significant Decrease in Short Interest

Biomerica, Inc. (NASDAQ:BMRA) was the target of a large decline in short interest in the month of January. As of January 30th, there was short interest totaling 74,357 shares, a decline of 15.7% from the January 15th total of 88,194 shares. Currently, 3.0% of the company’s shares are short sold. Based on an average trading volume of 17,670 shares, the short-interest ratio is currently 4.2 days. Based on an average trading volume of 17,670 shares, the short-interest ratio is currently 4.2 days. Currently, 3.0% of the company’s shares are short sold.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Biomerica stock. DRW Securities LLC increased its holdings in shares of Biomerica, Inc. (NASDAQ:BMRA) by 62.9% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 16,925 shares of the company’s stock after buying an additional 6,533 shares during the period. DRW Securities LLC owned about 0.56% of Biomerica worth $43,000 at the end of the most recent quarter. 22.28% of the stock is currently owned by institutional investors and hedge funds.

Biomerica Stock Down 2.6%

Shares of NASDAQ BMRA opened at $2.23 on Wednesday. Biomerica has a 52-week low of $2.11 and a 52-week high of $8.80. The business’s 50 day moving average is $2.49 and its two-hundred day moving average is $2.70. The firm has a market cap of $6.73 million, a price-to-earnings ratio of -2.40 and a beta of 0.19.

Biomerica (NASDAQ:BMRA) last issued its quarterly earnings data on Wednesday, January 14th. The company reported ($0.45) earnings per share for the quarter. Biomerica had a negative net margin of 90.29% and a negative return on equity of 83.73%. The firm had revenue of $1.21 million during the quarter.

About Biomerica

Biomerica, Inc is a developer, manufacturer and marketer of in vitro diagnostic tests for clinical diagnostic, life science research and food safety applications. The company’s product portfolio includes enzyme-linked immunosorbent assays (ELISAs), lateral flow immunoassays, point-of-care devices and specialty reagents designed to aid in the detection and monitoring of gastrointestinal, metabolic and autoimmune conditions. Biomerica’s diagnostics are used by hospitals, clinical and reference laboratories, and research institutions seeking solutions for early disease detection and patient management.

Key offerings from Biomerica include serological tests for celiac disease and gluten intolerance, quantitative assays for colorectal cancer screening markers such as M2-PK, and a range of point-of-care kits for metabolic monitoring.